BALB/c Nude Mice Were Injected Subcutaneously With 5 × 106 Cells (5 mice/cell line)
| Cells . | Experiment 1 (tumor size mm3) . | Experiment 2 (tumor size mm3) . |
|---|---|---|
| CD44− | 510; 486; 1296; 1181; 726 | 445; 1008; 405; 405; 1183 |
| Vector alone (CD44−) | 710; 384; 910; 343; 520 | ND |
| CD44+ (pooled) | 22; 13; 22; 0; 0 | 12; 24; 0; 0; 0 |
| CD44+ (single clone) | 16; 13; 0; 0; 0 | 18; 10; 10; 18; 0 |
| Cells . | Experiment 1 (tumor size mm3) . | Experiment 2 (tumor size mm3) . |
|---|---|---|
| CD44− | 510; 486; 1296; 1181; 726 | 445; 1008; 405; 405; 1183 |
| Vector alone (CD44−) | 710; 384; 910; 343; 520 | ND |
| CD44+ (pooled) | 22; 13; 22; 0; 0 | 12; 24; 0; 0; 0 |
| CD44+ (single clone) | 16; 13; 0; 0; 0 | 18; 10; 10; 18; 0 |
Abbreviation: ND, not determined.
After 2 months mice were sacrificed and tumors measured using a caliper. CD44− tumor cells have significant growth advantage in vivo. The original cell lines were derived from the intestines of CD44-deficient embryos after transformation with SV40 large T antigen. Transformed CD44−/− fibroblasts were transfected with CD44s or vector alone. The CD44-deficient embryos were obtained from breeding of homozygous-deficient mice (129J × C57BL/6; both H2-b).